CN Patent

CN107530349B — 作为a2b拮抗剂的黄嘌呤取代的炔基氨基甲酸酯/反式氨基甲酸酯

Assigned to Lewis and Clark Pharmaceuticals Inc · Expires 2021-01-08 · 5y expired

What this patent protects

本发明提供了作为A 2B 腺苷受体(AR)的选择性拮抗剂的黄嘌呤取代的炔基氨基甲酸酯/反式氨基甲酸酯及其衍生物，以及包含其的药物组合物。这些化合物和组合物可用作药剂。

USPTO Abstract

本发明提供了作为A 2B 腺苷受体(AR)的选择性拮抗剂的黄嘌呤取代的炔基氨基甲酸酯/反式氨基甲酸酯及其衍生物，以及包含其的药物组合物。这些化合物和组合物可用作药剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN107530349B
Jurisdiction
CN
Classification
—
Expires
2021-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Lewis and Clark Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.